"Not So Different": How a Value-Based Pathway Led to Increased Biosimilar Use

This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use. 
September 01, 2019
It's no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, with few products launched relative to those approved, low uptake of the products that are available, and formulary restrictions that sometimes favor branded biologics over biosimilar options. But given the benefits that biosimilars can provide, some physicians are taking matters into their own hands with concerted efforts to bring these products to the clinic. This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use. 



Read more about the value-based pathway here, and find the Articularis Rheumatology Network here

x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.